NATALIE GIBSON: Open Payments
NPI 1528419330 · PROVIDENCE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$909 in 55 payments from 18 companies in 2025. Trend: 2023 $669 · 2024 $845 · 2025 $909
Food & beverage: $909
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Amgen Inc. | 4 | $70 |
| Alkermes, Inc. | 3 | $51 |
| Lundbeck LLC | 3 | $46 |
| Grifols USA, LLC | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $29 |
| Indivior Inc. | 1 | $25 |
| Exact Sciences Corporation | 1 | $21 |
Products named: VRAYLAR, TRINTELLIX, QULIPTA, REXULTI, UBRELVY, EVENITY, ARISTADA, Prolastin-C Liquid.
Industry payments across UT — which companies pay providers there.
